FANCG Gene

Alternative Names

  • FANCG
  • X-Ray Repair, Complementing Defective, in Chinese Hamster, 9
  • XRCC9
Back to search Result
OMIM Number

602956

NCBI Gene ID

2189

Uniprot ID

O15287

Length

6,108 bases

No. of Exons

14

No. of isoforms

1

Protein Name

Fanconi anemia group G protein

Molecular Mass

68554 Da

Amino Acid Count

622

Genomic Location

chr9:35,073,835-35,079,942

Gene Map Locus
9p13.3

Description

The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group G. [From RefSeq]

Molecular Genetics

FANCG mutations account for 10% of all Fanconi anemia cases. More than 50 FANCG pathogenic mutations have been described to date. FANCG is also known as the human XRCC9 gene since it complements the MMC-sensitive Chinese hamster mutant UV40. The product of the gene might be involved in DNA post-replication repair or cell cycle checkpoint control. FANCG gene is localized to chromosome band 9p13.

Epidemiology in the Arab World

View Map
Variant NameCountryGenomic LocationClinvar Clinical SignificanceCTGA Clinical Significance Condition(s)HGVS ExpressionsdbSNPClinvar
NM_004629.1:c.1761-1G>CLebanonNC_000009.12:g.35074217C>GPathogenicPathogenicFanconi Anemia, Complementation Group GNG_007312.1:g.10800G>C; NM_004629.1:c.1761-1G>C6713
NM_004629.2:c.1298G>C LebanonNC_000009.12:g.35075600C>GUncertain SignificanceUncertain SignificanceBreast CancerNG_007887.1:g.2143G>C; NM_004629.2:c.1298G>C ; NP_004620.1:p.Arg433Pro748738986836235
NM_004629.2:c.181C>TLebanonchr9:35078731Likely PathogenicLikely PathogenicFanconi Anemia, Complementation Group GNG_007312.1:g.6286C>T; NM_004629.2:c.181C>T; NP_004620.1:p.Pro61Ser931163229569286
NM_004629.2:c.452T>ALebanonchr9:35078199PathogenicFanconi Anemia, Complementation Group GNG_007312.1:g.6818T>A; NM_004629.2:c.452T>A; NP_004620.1:p.Leu151Ter

Other Reports

Lebanon

de Winter et al. (1998) analyzed the FANCG gene in two sibs (a male and a female) from a consanguineous Lebanese family. De Winter et al. (1998) concluded that complementation group G Fanconi anemia was caused in these patients by homozygosity for a splice acceptor site G-C substitution at IVS13-1, which results in a truncated protein.

Palestine

Tamary et al. (2004) investigated the molecular basis of Fanconi anemia (FANCA and FANCG) in three consanguineous families with nine patients and an additional unrelated patient. In one consanguineous family with three affected individuals, Tamary et al. (2004) applied SSCP analysis coupled with RT-PCR and DNA sequencing for the exons of the FANCG gene and identified a unique disease-causing splice-site IVS4+3A-G mutation. cDNA analysis of the mutation suggested exon 4 skipping in FANCG gene that caused an out-of-frame mRNA which predicted a new termination codon (TAA, at new codon 107), probably resulting in a truncated protein.

 

Saudi Arabia

Ghazwani et al. (2016) reviewed Fanconi anemia (FA) patients at a Saudi Arabian hospital to determine their underlying genetic mutations.  Ten FA patients from consanguineous families were identified for the study.  Of these, a 21-year-old Saudi female was found to have a homozygous c.637_643del in the FANCG gene, resulting in a p.Tyr213Lysfs*6 substitution.  This mutation was not found in 50 ethnically-matched, non-FA controls.  The patient’s symptoms included micrognathia, café au lait spots, a short stature and an ectopic kidney.  She suffered from severe aplastic anemia and eventually, acute myeloid leukemia.  This mutation had been found to be frequent in sub-Saharan African FA patients and has been associated with an increased risk of hematological malignancy.  The authors also noted that, unlike FANCG, most Saudi mutations were found in downstream FA pathway genes. The FANCD2 protein monoubiquitination assay would thus be unable to detect most Saudi FA cases.   

© CAGS 2024. All rights reserved.